

6. Literaturverzeichnis

1. Allen U, Hebert D, Moore D, Dror Y, Wasfy S. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience. *Pediatr Transplant* 2001; **5**: 198.
2. Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. *Am J Respir Crit Care Med* 1996; **154**: 1712.
3. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. *J Exp Med* 1999; **190**: 567.
4. Babel N, Hammer MH, Reinke P. [Adoptive transfer of Epstein-Barr virus-specific T-lymphocytes in chronic active Epstein-Barr infection]. *Dtsch Med Wochenschr* 2003; **128**: 548.
5. Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ, Homan van der Heide JJ, Veeger NJ, Kluin PM, Kluin-Nelemans HC. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. *Clin Transplant* 2005; **19**: 327.
6. Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P, Garnier JL, Le Bidois J, Le Deist F, Blanche S, Fischer A. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. *Blood* 1998; **92**: 3137.
7. Beynet DP, Wee SA, Horwitz SS, Kohler S, Horning S, Hoppe R, Kim YH. Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. *Arch Dermatol* 2004; **140**: 1140.
8. Birkeland SA, Andersen HK, Hamilton-Dutoit SJ. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. *Transplantation* 1999; **67**: 1209.
9. Boyle GJ, Michaels MG, Webber SA, Knisely AS, Kurland G, Cipriani LA, Griffith BP, Fricker FJ. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. *J Pediatr* 1997; **131**: 309.
10. Buell JF, Gross TG, Hanaway MJ, Trofe J, Muthiak C, First MR, Alloway RR, Woodle ES. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. *Transplant Proc* 2005; **37**: 956.

11. Burton C, Linch D, Hoskin P, Milligan D, Dyer MJ, Hancock B, Mouncey P, Smith P, Qian W, MacLennan K, Jack A, Webb A, Cunningham D. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. *Br J Cancer* 2006; **94**: 806.
12. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. *Blood* 2006; **108**: 1504.
13. Caillard S, Lachat V, Moulin B. Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. PTLD French Working Group. *Transpl Int* 2000; **13 Suppl 1**: S388.
14. Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R, Knowles DM. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. *Blood* 1998; **92**: 2294.
15. Chau I, Webb A, Cunningham D, Hill M, Rao S, Ageli S, Norman A, Gill K, Howard A, Catovsky D. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. *Br J Haematol* 2001; **115**: 786.
16. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. *J Clin Oncol* 1999; **17**: 1244.
17. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN, Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L, Milpied N. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. *Blood* 2006; **107**: 3053.
18. Choquet S, Oertel S, Leblond V, Riess H, Doerken B, Trappe R. Rituximab in the management of post-transplantation lymphoproliferative disorder: proceed with caution. *Ann Hematol* 2007; eingereicht.
19. Choquet S, Trappe R, Leblond V, Jaeger U, Davi F, Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Efficacy, toxicity and factors predicting survival: A retrospective study of 26 cases with a long term follow up of 8.8 years. *Haematologica* 2007; **92**: 273-274.

20. Ciancio G, Siquijor AP, Burke GW, Roth D, Cirocco R, Esquenazi V, Byrne GE, Jr., Miller J. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. *Clin Transplant* 1997; **11**: 243.
21. Comoli P, Labirio M, Basso S, Baldanti F, Grossi P, Furione M, Vigano M, Fiocchi R, Rossi G, Ginevri F, Gridelli B, Moretta A, Montagna D, Locatelli F, Gerna G, Maccario R. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. *Blood* 2002; **99**: 2592.
22. Comoli P, Maccario R, Locatelli F, Valente U, Basso S, Garaventa A, Toma P, Botti G, Melioli G, Baldanti F, Nocera A, Perfumo F, Ginevri F. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. *Am J Transplant* 2005; **5**: 1415.
23. Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). *Cancer* 2004; **101**: 1835.
24. Czuczman MS, Grillo-Lopez AJ, Alkuzweny B, Weaver R, Larocca A, McLaughlin P. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. *Leuk Lymphoma* 2006; **47**: 1830.
25. Dotti G, Fiocchi R, Motta T, Gamba A, Gotti E, Gridelli B, Borleri G, Manzoni C, Viero P, Remuzzi G, Barbui T, Rambaldi A. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. *Transplantation* 2000; **69**: 827.
26. Duvoux C, Pageaux GP, Vanlemmens C, Roudot-Thoraval F, Vincens-Rolland AL, Hezode C, Gaulard P, Miguet JP, Larrey D, Dhumeaux D, Cherqui D. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. *Transplantation* 2002; **74**: 1103.
27. Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthoff KM, Schuster SJ, Nasta SD, Stadtmauer EA, Tsai DE. Treatment of PTLD with rituximab or chemotherapy. *Am J Transplant* 2006; **6**: 569.
28. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 2005; **23**: 4117.
29. Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaegle ML, Meyer C, Epailly E, Chenard MP, Lioure B, Natarajan-Ame S, Maloisel F, Lutun P, Kessler R, Moulin B, Bergerat

- JP, Wolf P, Herbrecht R. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. *Br J Haematol* 2006; **134**: 602.
30. Gao SZ, Chaparro SV, Perloth M, Montoya JG, Miller JL, DiMiceli S, Hastie T, Oyer PE, Schroeder J. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. *J Heart Lung Transplant* 2003; **22**: 505.
 31. Garrett TJ, Chadburn A, Barr ML, Drusin RE, Chen JM, Schulman LL, Smith CR, Reison DS, Rose EA, Michler RE, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. *Cancer* 1993; **72**: 2782.
 32. Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM, McGregor CG. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. *Leuk Lymphoma* 2005; **46**: 191.
 33. Gill PS, Levine AM, Krailo M, Rarick MU, Loureiro C, Deyton L, Meyer P, Rasheed S. AIDS-related malignant lymphoma: results of prospective treatment trials. *J Clin Oncol* 1987; **5**: 1322.
 34. Girouard C, Dufresne J, Imrie K, Stewart AK, Brandwein J, Prince HM, Pantolony D, Keating A, Crump M. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. *Ann Oncol* 1997; **8**: 675.
 35. Gnaoui T, Dupuis J, Joly B, Belhadj K, Rahmouni A, Copie-Bergman C, Allain A, Tabah-Fish I, Reyes F, Haioun C. Rituximab, gemcitabine and oxaliplatin (R-GEMOX): a promising regimen for refractory/relapsed b-cell lymphoma. *Blood (ASH Annual Meeting Abstracts)* 2004; **104**: 2483.
 36. Grefer J, Oertel SH, Hummel M. B-cell depletion and recovery after treatment with the anti-CD20 monoclonal antibody rituximab in patients with posttransplant lymphoproliferative disorder (PT-LPD). *Blood* 2001; **98**: 242b.
 37. Gross TG. Low-dose chemotherapy for children with post-transplant lymphoproliferative disease. *Recent Results Cancer Res* 2002; **159**: 96.
 38. Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. *J Clin Oncol* 2005; **23**: 6481.
 39. Haddad E, Paczesny S, Leblond V, Seigneurin JM, Stern M, Achkar A, Bauwens M, Delwail V, Debray D, Duvoux C, Hubert P, Hurault de Ligny B, Wijdenes J, Durandy A, Fischer A. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. *Blood* 2001; **97**: 1590.

40. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. *Semin Diagn Pathol* 1997; **14**: 8.
41. Heo JS, Park JW, Lee KW, Lee SK, Joh JW, Kim SJ, Lee HH, Lee DS, Choi SH, Seo JM, Choe YH. Posttransplantation lymphoproliferative disorder in pediatric liver transplantation. *Transplant Proc* 2004; **36**: 2307.
42. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. *Nat Med* 1996; **2**: 551.
43. Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L, Atchison RW, Karrer F, Nalesnik MA, Starzl TE. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. *Transplantation* 1988; **45**: 719.
44. Jain AB, Marcos A, Pokharna R, Shapiro R, Fontes PA, Marsh W, Mohanka R, Fung JJ. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. *Transplantation* 2005; **80**: 1692.
45. Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dorken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. *Ann Oncol* 2005; **16**: 1359.
46. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. *Blood* 2005; **106**: 1538.
47. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, Herndier B, Northfelt DW, Huang J, Tulpule A, Levine AM. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. *N Engl J Med* 1997; **336**: 1641.
48. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. *Blood* 2004; **103**: 3684.
49. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. *Blood* 1995; **85**: 552.

50. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, Gandjbakhch I, Binet JL, Raphael M. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? *J Clin Oncol* 1998; **16**: 2052.
51. Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, Nguyen Quoc S, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. *J Clin Oncol* 2001; **19**: 772.
52. Leblond V, Sutton L, Dorent R, Davi F, Bitker MO, Gabarre J, Charlotte F, Ghoussoub JJ, Fourcade C, Fischer A, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. *J Clin Oncol* 1995; **13**: 961.
53. Lee LS, Carr-Locke DL. A case report--posttransplantation lymphoproliferative disorder. *MedGenMed* 2003; **5**: 14.
54. Levine AM, Sullivan-Halley J, Pike MC, Rarick MU, Loureiro C, Bernstein-Singer M, Willson E, Brynes R, Parker J, Rasheed S, et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. *Cancer* 1991; **68**: 2466.
55. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. *N Engl J Med* 1998; **338**: 1413.
56. Linch DC, Smith P, Hancock BW, Hoskin PJ, Cunningham DC, Newland AC, Milligan D, Stevenson PA, Wood JK, MacLennan KA, Vaughan B, Vaughan G, Gregory WM. A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. *Ann Oncol* 2000; **11 Suppl 1**: 87.
57. Linch DC, Vaughan Hudson B, Hancock BW, Hoskin PJ, Cunningham DC, Newland AC, Milligan DW, Stevenson PA, Wood JK, MacLennan KA, Anderson L, Gregory WM, Vaughan Hudson G. A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. *Br J Cancer* 1996; **74**: 318.
58. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, Wilson WH. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. *Blood* 2003; **101**: 4653.
59. Mamzer-Bruneel MF, Lome C, Morelon E, Levy V, Bourquelot P, Jacobs F, Gessain A, Mac Intyre E, Brousse N, Kreis H, Hermine O. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. *J Clin Oncol* 2000; **18**: 3622.

60. Mentzer SJ, Perrine SP, Faller DV. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. *Transpl Infect Dis* 2001; **3**: 177.
61. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. *J Clin Oncol* 1995; **13**: 588.
62. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. *J Clin Oncol* 1999; **17**: 3776.
63. Muller AR, Pascher A, Platz KP, Neuhaus P. [Small bowel transplantation - current status and initial results]. *Zentralbl Chir* 2003; **128**: 849.
64. Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. *Recent Results Cancer Res* 2002; **159**: 9.
65. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? *Am J Surg Pathol* 2000; **24**: 375.
66. Norin S, Kimby E, Ericzon BG, Christensson B, Sander B, Soderdahl G, Hagglund H. Posttransplant lymphoma--a single-center experience of 500 liver transplantations. *Med Oncol* 2004; **21**: 273.
67. Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dorken B, Riess H, Gartner B. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. *Ann Hematol* 2006; **85**: 478.
68. Oertel SH, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB. Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. *Br J Haematol* 2002; **118**: 1120.
69. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N, Trappe RU, Jonas S, Hummel M, Anagnostopoulos I, Dorken B, Riess HB. Effect of Anti-CD 20 Antibody Rituximab in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD). *Am J Transplant* 2005; **5**: 2901.
70. Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. *Clin Cancer Res* 2003; **9**: 3945S.

71. Paranjothi S, Yusen RD, Kraus MD, Lynch JP, Patterson GA, Trulock EP. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. *J Heart Lung Transplant* 2001; **20**: 1054.
72. Pfreundschuh M, Kloess M, Schmits R, Zeynalova S, Lengfelder E, Franke A, Steinhauer H, Reiser M, Clemens M, Nickenig C, de Wit M, Hoffmann M, R. M, B. M, Ho A, Truemper L, Eimermacher H, Mergenthaler H, Liersch R, Duehrsen U, Leopold B, Hartmann F, Poeschel V, Schmitz N, Loeffler M. Six, not eight cycles of bi-weekly CHOP with Rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large b-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). *Blood (ASH Annual Meeting Abstracts)* 2005; **106**: 13.
73. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *Lancet Oncol* 2006; **7**: 379.
74. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med* 1995; **333**: 1540.
75. Pickhardt PJ, Siegel MJ. Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. *Radiology* 1999; **213**: 73.
76. Poirel HA, Bernheim A, Schneider A, Meddeb M, Choquet S, Leblond V, Charlotte F, Davi F, Canioni D, Macintyre E, Mamzer-Bruneel MF, Hirsch I, Hermine O, Martin A, Cornillet-Lefebvre P, Patey M, Toupance O, Kemeny JL, Deteix P, Raphael M. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status. *Transplantation* 2005; **80**: 176.
77. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. *J Clin Oncol* 2001; **19**: 2171.
78. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. *Hematol Oncol Clin North Am* 1997; **11**: 937.
79. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. *Lancet* 1995; **345**: 9.

80. Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. *Blood* 2002; **100**: 4059.
81. Seyfarth B, Josting A, Dreyling M, Schmitz N. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. *Br J Haematol* 2006; **133**: 3.
82. Smets F, Vajro P, Cornu G, Reding R, Otte JB, Sokal E. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. *Transplantation* 2000; **69**: 982.
83. Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, Rossi G, Nigra E, Berretta M, Cattaneo C, Rieger AC, Vaccher E, Tirelli U. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. *Blood* 2005; **105**: 1891.
84. Spina M, Sparano JA, Jaeger U, Rossi G, Tirelli U. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. *Aids* 2003; **17**: 137.
85. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW, Jr., Hardesty RL, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. *Lancet* 1984; **1**: 583.
86. Suryanarayan K, Natkunam Y, Berry G, Bangs CD, Cherry A, Dahl G. Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation. *J Pediatr Hematol Oncol* 2001; **23**: 452.
87. Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. *Transpl Int* 2006; **19**: 259.
88. Swinnen LJ. Diagnosis and treatment of transplant-related lymphoma. *Ann Oncol* 2000; **11 Suppl 1**: 45.
89. Taylor AL, Bowles KM, Callaghan CJ, Wimperis JZ, Grant JW, Marcus RE, Bradley JA. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. *Transplantation* 2006; **82**: 375.
90. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. *Crit Rev Oncol Hematol* 2005.

91. Trappe R, Oertel S, Riess H. HIV-assoziierte Lymphome und Posttransplantationslymphome. *Der Onkologe* 2006; **12**: 641.
92. Trappe R, Oertel SH, Choquet S, LeBlond V, Papp-Vary M, Riess H. Sequential Treatment With The anti-CD 20 Antibody Rituximab And CHOP+GCSF Chemotherapy In Patients With Post-transplant Lymphoproliferative Disorder (PTLD): First Results Of A Multicenter Phase II Study. *Blood (ASH Annual Meeting Abstracts)* 2005; **106**: 932.
93. Trappe R, Riess HB, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Doerken B, Oertel S. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single agent rituximab. *Transplantation* 2007; im Druck.
94. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, Schuster SJ, Porter DL, Montone KT, Stadtmauer EA. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. *Transplantation* 2001; **71**: 1076.
95. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemester FB, Redman JR, Swan F, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). *Blood* 1988; **71**: 117.
96. Velasquez WS, McLaughlin P, Tucker S, Hagemester FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. *J Clin Oncol* 1994; **12**: 1169.
97. Vellenga E, Notenboom A, van 't Veer M, Zijlstra J, Fibbe W, van Oers R, van Imhoff G, Lugtenburg E, Huijgens P. Rituximab (Mabthera) Improves the Treatment Results of DHAP-VIM-DHAP and ASCT in Relapsed/Progressive Aggressive CD20+ NHL. A Prospective Randomized HOVON Trial. *Blood (ASH Annual Meeting Abstracts)* 2006; **108**.
98. Wu L, Rappaport DC, Hanbidge A, Merchant N, Shepherd FA, Greig PD. Lymphoproliferative disorders after liver transplantation: imaging features. *Abdom Imaging* 2001; **26**: 200.